A Hybrid model was used to forecast the total number of cases, hospitalization and ICU requirements, and the total number of deaths at national level.
|Prevention of infection||52%|
|Prevention of symptomatic diseases||85%, for 65+ age groups; 74% for others|
|Prevention of severe or critical cases||100%|
Vaccine type: AstraZeneca. The above efficacy values only work for D614G and B.1.1.7 variants, and the efficacy is critically low for South African variant.
|Intermediate Clinical Intervention||With current clinical interventions which are helpful in reducing case severity and fatality.|
|Lowest Clinical Intervention||If clinical interventions are not effective enough in reducing case severity and fatality, due to resource overwhelming or other reasons.|
|Highest Clinical Intervention||If clinical interventions are effective in reducing the continuously increasing case severity and fatality.|
These values can be affected by many factors, but availability of hospitalization, ICU beds, oxygen cylinders and mechanical ventilators are the most common ones.
|Number||Country||Total Number of Cases||Total Number of Deaths||Case Fatality in Percent|